Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ADAPTcycle
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
- NCT04055493 ↗
- Active, not recruiting
- Women's Cancer Study Group GmbH
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| X threads | 9 | |
| Podcasts | 7 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Endocrine Therapy Plus Ribociclib Versus Chemotherapy in Intermediate Risk, HR+/HER2- Early Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer Female
- Interventions
- Ribociclib 200Mg Oral Tablet
- Arms
- Ribociclib plus ET · Experimental
- Standard-of-care chemotherapy · No intervention
- Enrollment
- 1,684
- Primary outcomes
- invasive disease-free survival (iDFS)
- distant disease-free survival (dDFS)
- Sponsor
- Women's Cancer Study Group GmbH with Novartis, Genomic Health®, Inc.
- Start
- Jul 2, 2019
- Primary completion
- Jul 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04055493 · updated Oct 9, 2026
Publications
linked from the registry- Klier K, Patel YJ, Schinkothe T, Harbeck N, Schmidt A. Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study. JMIR Cardio. 2023 Sep 11;7:e48096. doi: 10.2196/48096. PubMed 37695655